Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.33 |
| ▸ | PDE4A | P27815 | 3/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582946 | 0.99 | NR3C1 (0.38) | NR3C1POLBPDE4BPDE4APDE4C | |
| SCHEMBL583871 | 0.98 | NR3C1 (0.37) | NR3C1POLBPDE4BPDE4APDE4C | |
| SCHEMBL583483 | 0.97 | NR3C1 (0.40) | NR3C1POLBPDE4BPDE4APDE4C | |
| SCHEMBL583680 | 0.96 | NR3C1 (0.41) | NR3C1POLBPDE4BPDE4APDE4C | |
| SCHEMBL583441 | 0.95 | NR3C1 (0.40) | NR3C1POLBPDE4BPDE4APDE4C | |
| SCHEMBL582573 | 0.87 | NR3C1 (0.38) | NR3C1POLBPDE4BPDE4APDE4C | |
| SCHEMBL1472103 | 0.83 | POLB (0.39) | NR3C1POLBPDE4BPDE4APDE4C | |
| SCHEMBL580665 | 0.83 | POLB (0.47) | NR3C1POLBPDE4BPDE7A | |
| SCHEMBL583007 | 0.82 | POLB (0.45) | POLBPDE4BPDE7A | |
| SCHEMBL582557 | 0.82 | POLB (0.44) | POLBPDE4BPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124944-B1 | Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LAB LTD (IN) | 2012-02-15 | — | — | EP | claimed |
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-18 | — | — | US | claimed |
| US-20100022571-A1 | SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-28 | — | — | US | claimed |
| US-8420666-B2 | Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100022571-A1 | SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE4A, PDE3A | NR3C1 519/4885POLB 1725/4885PDE4B 5/4885 |
| US-20100022571-A1 | SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | PDE4B, PDE4A, PDE3B | NR3C1 3791/4885POLB 749/4885PDE4B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.